There are three likely waves in the near future for small-molecule GLP-1RAs
In addition to these widely used AOMs, Exenatide, one of the earliest GLP-1 RAs approved by the FDA and EMA for T2DM management, is not indicated for weight management but remains clinically relevant, particularly in older adults with comorbid obesity and T2DM, given its long-term clinical experience and established tolerability profile [26,27,28]
Anthem is an affiliate of the larger Blue Cross Blue Shield Association
For instance, oral administration of LA loaded into thermally hydrocarbonized porous silicon (THCPSi) particles stimulated GLP1 release via GPR120 in a sustained manner and inhibited the food intake in mice [155] (Fig
Availability of data and materials All data generated or analyzed during this study are included in this published article and its supplementary information files (Additional File 2)